We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Get Rid of Aimmune Therapeutics (AIMT) Now?
Read MoreHide Full Article
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Aimmune Therapeutics, Inc. , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in AIMT.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen two estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of $1.97 a share a month ago to its current level of a loss of $2.72.
Also, for the current quarter, Aimmune Therapeutics has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 53 cents a share from a loss of 47 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 9.4% in the past month.
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.
If you are still interested in the Medical - Biomedical and Genetics industry, you may instead consider a better-ranked stock – Anthera Pharmaceuticals, Inc. (ANTH - Free Report) . The stock currently holds a Zacks Rank #1 Strong (Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank stocks here.
Looking for Ideas with Even Greater Upside?
Most of Zacks’ investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Should You Get Rid of Aimmune Therapeutics (AIMT) Now?
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Aimmune Therapeutics, Inc. , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in AIMT.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen two estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of $1.97 a share a month ago to its current level of a loss of $2.72.
Also, for the current quarter, Aimmune Therapeutics has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 53 cents a share from a loss of 47 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 9.4% in the past month.
Aimmune Therapeutics, Inc. Price and Consensus
Aimmune Therapeutics, Inc. Price and Consensus | Aimmune Therapeutics, Inc. Quote
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.
If you are still interested in the Medical - Biomedical and Genetics industry, you may instead consider a better-ranked stock – Anthera Pharmaceuticals, Inc. (ANTH - Free Report) . The stock currently holds a Zacks Rank #1 Strong (Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank stocks here.
Looking for Ideas with Even Greater Upside?
Most of Zacks’ investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information>>